Kapitalisasi marang bathi Syros (SYRS)
Syros Pharmaceuticals (SYRS) develops targeted oncology drugs based on gene regulation mechanisms, which protects the business from price wars through patents. Management efficiently allocates resources, prioritizing the proof of therapeutic benefit for its systems. Partner laboratories and facilities are operating without disruption. The market trend shows a P/E ratio of 0.00, confirming the current asset valuation.
Rincian metrik komprehensif lan analitis Syros (SYRS)
- rega saham lan prakiraan rega para ahli:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data liabilitas lan likuiditas perusahaan:
Utang Agregat marang Ekuitas Syros Pharmaceuticals|SYRS - Utang jangka dawa marang modal|Rasio tanggungan utang jangka cendhak marang modal Syros Pharmaceuticals, Inc|SYRS - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Syros Pharmaceuticals, Inc.|SYRS - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Syros Pharmaceuticals|Indikator likuiditas cepet syros.com
- rincian bathi lan kelipatan pasar:
SYRS - Bathi resik|Proyeksi bathi mangsa ngarep Syros Pharmaceuticals|SYRS - Pangali P/E|Prakiraan rega marang bathi Syros Pharmaceuticals Inc.|SYRS - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Syros Pharmaceuticals, Inc.|SYRS - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Syros Pharmaceuticals|SYRS - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan syros.com|SYRS - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Syros Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
Ringkesan analisis perusahaan:SYRS, syros.com
Market expectations often diverge from the actual financial stability of biopharmaceutical startups. The P/E ratio determines business value through the ratio of market capitalization to net income. By analyzing P/E valuation trends, an investor can discern the extent of the premium paid for future growth. For Syros Pharmaceuticals (SYRS), this metric loses its classical meaning due to a lack of profitability. Negative values confirm critical capital burn and an operational crisis.
Analisis perusahaan pesaing
TEM: Nilai perusahaan marang bathi resik|Rasio rega marang bathi Qiagen (QGEN)|IONS - Kapitalisasi marang bathi|Rasio rega marang bathi Repligen Corp. RGEN|Periode bali modal bisnis Avidity Corp (RNA)|CRSP: Koefisien rega marang bathi|Nilai perusahaan marang bathi resik WGS (genedx.com)|Ultragenyx (RARE) - Rasio rega marang bathi|Kapitalisasi marang bathi resik BEAM (Beam Therapeutics Inc)|SRPT (Sarepta Therapeutics Inc) - Pangali P/E|TWST: Nilai perusahaan marang bathi resik|Pangali P/E TXG|Pangali P/E intelliatx.com (NTLA)|Rasio rega marang bathi Stoke Therapeutics, Inc. STOK|Nilai perusahaan marang bathi resik BLFS|WVE - Rasio rega marang bathi|Maze Therapeutics Corp (MAZE) - Koefisien rega marang bathi|SION: Pangali P/E|primemedicine.com (PRME) - Pangali P/E|TSHA (Taysha Gene Therapies, Inc.) - Pangali P/E|Koefisien rega marang bathi uniQure NV (QURE)|Pangali P/E MGTX|RGNX - Kapitalisasi marang bathi|Solid Biosciences Inc. - Koefisien rega marang bathi|Pangali P/E ocugen.com OCGN|PACB: Koefisien rega marang bathi|Benitec Biopharma Inc - Rasio rega pasar marang bathi resik|DSGN: Pangali P/E|RCKT - Periode bali modal bisnis|FDMT (4D Molecular Therapeutics) - Pangali P/E|Koefisien rega marang bathi Lexeo (LXEO)|Pangali P/E KRRO|Pangali P/E Editas Medicine Inc (EDIT)|Rasio rega marang bathi Silence Therapeutics Inc. SLN|ProQR - Rasio rega marang bathi|CDXS - Rasio rega marang bathi|Periode bali modal bisnis sangamo.com SGMO|nautilus.bio (NAUT) - Rasio rega marang bathi|MGX - Periode bali modal bisnis|Koefisien rega marang bathi DTIL|Kapitalisasi marang bathi Generation Bio Corp GBIO|Rasio rega marang bathi Boundless Bio, Inc. (BOLD)|XCUR (exicuretx.com) - Nilai perusahaan marang bathi resik|Rasio rega marang bathi Imunon IMNN|Periode bali modal bisnis Phio Pharmaceuticals Corp (PHIO)|Mustang Bio Corp - Pangali P/E|RNAZ (TransCode Therapeutics) - Pangali rega marang bathi|bionanogenomics.com (BNGO) - Rasio rega marang bathi|Pangali rega marang bathi APDN|BLUE (bluebird bio) - Pangali P/E|Pangali P/E ImmunoPrecise|Rasio rega marang bathi Omega (OMGA)|Periode bali modal bisnis Singular Genomics Corp|Regulus Therapeutics - Koefisien rega marang bathi|telesisbio.com (TBIO) - Kapitalisasi marang bathi|TCON - Rasio rega marang bathi|Nilai perusahaan marang bathi resik UBX (Unity Biotechnology Inc.)
